TLR8: A Closer Look at Its Role in Human Inflammation

TLR8 is an immune sensor that sits inside the endosomes of certain white blood cells, where it detects fragments of single-stranded RNA from bacteria, viruses, and even the body’s own damaged cells. When it encounters these fragments, it triggers a cascade of inflammatory signals that can help clear infections but, when dysregulated, can also drive autoimmune disease, neurodegeneration, and complications in pregnancy. The receptor has attracted growing research attention because it behaves quite differently in humans than in mice, which means decades of rodent studies missed much of what it does. That gap is now closing, and TLR8 is emerging as both a promising drug target and a key piece of the puzzle in understanding chronic inflammation.

How TLR8 Detects RNA

TLR8 is shaped like a horseshoe, built from repeating structural units called leucine-rich repeats. Two copies of the protein come together to form a dimer, and this dimer has two distinct pockets that work in tandem. The first pocket, located at the interface where the two halves meet, binds uridine, a building block of RNA. The second pocket sits along the inner curve of the horseshoe and grabs short stretches of RNA a few nucleotides long. When both pockets are occupied at the same time, TLR8 activation is strongest.¹ Mutagenesis experiments have confirmed that both binding sites are essential: knock either one out and the receptor goes silent.²

This two-site design is not just a structural curiosity. It means TLR8 does not respond to intact, full-length RNA drifting through the cell. Instead, it responds to degradation products, the small pieces left after enzymes chew up RNA inside the endosome. The receptor essentially waits for proof that foreign material has been processed and broken down before sounding the alarm.

The Activation Switch Inside the Endosome

Before TLR8 can even begin sensing RNA, it needs to be unlocked. The receptor is manufactured with a built-in safety latch: a stretch of amino acids called the Z-loop, located between two of its structural repeats, that must be cut by enzymes before the receptor can form its active dimer. Without this cleavage, TLR8 cannot dimerize at all, regardless of how much RNA is present.³ Both furin-like enzymes and cathepsins contribute to cutting the Z-loop, and this processing happens specifically inside the endosomal compartment.⁴

This layered security system matters. Because TLR8 can only fire after being cleaved inside endosomes and then encountering RNA degradation products in that same compartment, the receptor is unlikely to be accidentally triggered by the cell’s own cytoplasmic RNA. The location is the safeguard: endosomal RNA is, under normal circumstances, material the cell has engulfed from outside or swept up from dying neighbors.

What Happens After TLR8 Fires

Once activated, TLR8 recruits the adaptor protein MyD88 and launches signaling pathways that produce inflammatory cytokines. But TLR8 does not behave identically to its close relative TLR7, even though both sense RNA. Research comparing the two receptors has found that TLR7 activates both the IRF and NF-κB signaling branches roughly equally, while TLR8 is biased toward NF-κB and drives that pathway more strongly.⁵ In practical terms, NF-κB activation leads to production of pro-inflammatory molecules like TNF and IL-6, while the IRF branch is more associated with type I interferons used in antiviral defense.

That said, TLR8 is not locked out of the interferon response. In human monocytes, TLR8 sensing of bacterial RNA from Staphylococcus aureus triggers the transcription factor IRF5 through a signaling chain involving TAK1 and IKKβ, leading to production of IFN-β and IL-12.⁶ A recently developed inhibitor that blocks the TIRAP-MyD88 interaction was shown to suppress TLR8-induced production of IFN-β, IL-12p40, and IL-12p70 in human monocytes, without affecting TNF or IL-6, which suggests the interferon arm of TLR8 signaling can be selectively targeted.⁷

TLR8 also cooperates with other sensors. When TLR8 agonists are combined with activators of RIG-I-like receptors, which are a separate class of RNA sensors in the cytoplasm, the result is significantly higher production of IL-12p70 and a stronger type I interferon response than either sensor alone would generate.⁸

Which Cells Express TLR8

TLR8 is not found on every immune cell. It is expressed primarily on monocytes and conventional dendritic cells, two cell types that are central to initiating and shaping inflammatory responses. Plasmacytoid dendritic cells, in contrast, do not express functional TLR8. Studies in both healthy individuals and patients with autoimmune conditions confirmed this pattern: stimulating plasmacytoid dendritic cells through TLR8 produced no interferon response, while monocytes responded robustly.⁹

This cell-type specificity is a key difference from TLR7, which is active in plasmacytoid dendritic cells and is the major driver of their interferon output. Because TLR8 is concentrated in monocytes and conventional dendritic cells, it plays a particularly important role in the early inflammatory phase of an infection, orchestrating cytokine production and activating downstream adaptive immunity through antigen presentation.

Why Mouse Models Missed So Much

For years, TLR8’s importance was underestimated, largely because standard laboratory mice have a version of TLR8 that does not respond to RNA ligands the way human TLR8 does. Rodent TLR8 fails to respond to ligand stimulation unless a synthetic polyT-oligodeoxynucleotide is added as a co-stimulus. A comparative study across eight species found that only mouse and rat TLR8 had this problem; the receptor in cattle, pigs, horses, sheep, and cats all responded without the co-stimulus. The difference traced to a five-amino-acid motif in the receptor’s ectodomain that rodents lack but other mammals retain.¹⁰

This species difference has had real consequences for the field. Research on TLR8’s role in inflammation has been “limited by its different function in human versus rodents,” as one group noted.¹¹ It means that many findings about innate immune sensing of RNA that were worked out in mice apply primarily to TLR7 and TLR9, while TLR8’s contribution to human immunity went unstudied for a long time. Researchers now work around the problem by using human primary cells, humanized mouse models, or transgenic mice engineered to express the human version of TLR8.

Sensing Bacteria and Viruses

TLR8 detects RNA from a wide range of pathogens. In human monocyte-derived macrophages, it has been unambiguously identified as the receptor for bacterial RNA, and it plays a non-redundant role in recognizing Streptococcus pyogenes, the bacterium behind strep throat and more severe invasive infections.¹² TLR8 also senses RNA from Staphylococcus aureus and Escherichia coli, and studies have identified it as a functional equivalent of TLR13, a bacterial-RNA sensor found in mice but absent from the human genome.¹³

On the viral side, TLR7 and TLR8 together serve as key sensors of SARS-CoV-2 RNA. Specific single-stranded RNA fragments from the virus activate both receptors in human macrophages and microglia, triggering cytokine release.¹⁴ This dual activation is thought to contribute both to effective viral clearance and to the excessive inflammation seen in severe COVID-19, though disentangling the individual contributions of TLR7 and TLR8 in vivo remains difficult.

TLR8 in the Brain

One of the more surprising developments in TLR8 research involves the brain. Microglia, the resident immune cells of the central nervous system, express TLR8 and can be activated by extracellular microRNAs that act as signaling molecules rather than performing their usual gene-regulation duties. Several microRNAs linked to Alzheimer’s disease and glioma, including miR-9-5p, miR-132-5p, and miR-340-3p, have been identified as TLR8 ligands. When human-derived microglia were exposed to these microRNAs, the cells produced IL-6 and TNF, changed their motility, and altered their ability to engulf debris. Blocking TLR8 with a selective inhibitor called CU-CPT9a abolished these effects. In co-culture experiments, exposure of microglia to miR-132-5p and miR-9-5p reduced the length of neurites growing from nearby neurons, suggesting that TLR8-driven microglial activation can directly harm nerve cells.¹⁵

Complementary work has shown that dying cortical neurons release specific microRNAs, including miR-100-5p and miR-298-5p, that enter microglia, localize to their endosomes, and directly bind human TLR8.¹⁶ Both of these microRNAs have been consistently linked to neurodegenerative diseases. The emerging picture is a vicious cycle: damaged neurons release RNA fragments that activate microglial TLR8, which drives inflammation that damages more neurons. Breaking that cycle is now a therapeutic goal.

When TLR8 Drives Disease

Overactive TLR8 signaling has been implicated in several autoimmune and autoinflammatory conditions. In systemic lupus erythematosus, TLR7, TLR8, and TLR9 are all thought to contribute to disease by recognizing self-derived nucleic acids and launching inflammatory cascades that sustain the immune attack on the body’s own tissues.¹⁷ In systemic sclerosis, monocytes show increased IL-10 responses when TLR8 is stimulated, pointing to aberrant TLR8 signaling as a feature of the disease.⁹

Some of the most dramatic evidence for TLR8’s inflammatory potential comes from rare genetic cases. Researchers identified six unrelated boys with gain-of-function mutations in TLR8 who developed a constellation of problems including neutropenia, recurrent infections, lymphoproliferation, impaired antibody production, and in some cases bone marrow failure. Their immune cells showed a proinflammatory phenotype with elevated cytokines and activated T cells alongside defective B-cell maturation.¹⁸ These cases illustrate that too much TLR8 activity does not simply cause inflammation; it can exhaust the immune system, leading paradoxically to both hyperinflammation and immunodeficiency.

The X-Chromosome Factor

TLR8 sits on the X chromosome, which immediately raises questions about sex differences. Women carry two copies of the X chromosome, and while one copy is normally silenced in each cell, TLR8 escapes this silencing. Using a technique called RNA FISH, researchers demonstrated that both copies of TLR8 are actively transcribed in monocytes and CD4+ T cells from women. Men with Klinefelter syndrome (who carry an extra X chromosome) showed a similar pattern. The result is that cells with two active copies of TLR8 are roughly sevenfold more frequent in women and Klinefelter men than in typical men.¹⁹

This escape from inactivation could help explain why autoimmune diseases that involve nucleic-acid-sensing receptors, such as lupus, are far more common in women. If female immune cells are, on average, producing more TLR8 protein, those cells may be more reactive to self-derived RNA. The same logic applies to TLR7, which also escapes X-chromosome inactivation and sits nearby on the same chromosome. Together, these findings suggest that sex differences in autoimmune susceptibility are partly hard-wired at the level of innate immune receptor expression.

Pregnancy and Preterm Birth

TLR8 also appears in an unexpected context: the membranes surrounding the fetus during pregnancy. When fetal membranes are exposed to bacterial lipopolysaccharide (a component of gram-negative bacterial cell walls), they upregulate a specific microRNA called miR-146a-3p, which then acts as a TLR8 ligand. This sets off a secondary wave of inflammation, including IL-8 and IL-1β production through the inflammasome. The microRNA was significantly elevated in fetal membranes from women who experienced preterm birth with chorioamnionitis, the infection-driven inflammation of fetal membranes. In mice engineered to lack both TLR7 and TLR8, exposure to lipopolysaccharide could initiate preterm labor but could not sustain it, and fetal membrane inflammation was reduced.²⁰

This mechanism represents a kind of inflammatory amplification loop. The initial bacterial insult activates one innate immune pathway (via TLR4, which senses lipopolysaccharide), which generates a microRNA danger signal that then activates a second pathway through TLR8. Intervening at the TLR8 step could, in theory, reduce the downstream inflammation that sustains preterm labor without blocking the initial bacterial detection entirely.

Cancer Immunotherapy

If TLR8 overactivation drives disease in autoimmune settings, the same inflammatory power becomes an asset in cancer, where the immune system often needs a push to attack tumors. In a systematic screen of pattern-recognition receptor agonists in tumor models, TLR8 agonists were the most potent at transforming the tumor immune environment into one that favors immune attack. They drove immune-cell infiltration, boosted the ability of dendritic cells and macrophages to engulf tumor material, recruited CD8+ and CD4+ T cells, reduced the proportion of regulatory T cells that suppress immune responses, and shifted innate immune cells toward tumor-killing phenotypes.²¹

Much of the preclinical work has used R848 (resiquimod), a dual TLR7/TLR8 agonist, packaged in nanoparticles to concentrate the drug within tumors. Nanoparticle-delivered R848 reprogrammed tumor-associated macrophages from a tumor-promoting state to a tumor-fighting state, controlled tumor growth as a monotherapy in mice, and even protected against rechallenge with the same tumor.²² Mannosylated nanoparticles designed to specifically target macrophages achieved similar reprogramming and converted immunologically “cold” tumors into “hot” ones with high T-cell infiltration.²³ The challenge, as always, is confining the inflammatory stimulus to the tumor. Systemic TLR8 activation would cause widespread inflammation, so delivery strategies that restrict the drug to the tumor microenvironment are essential.

Boosting Vaccines in Newborns

Newborn immune systems are notoriously difficult to vaccinate. They tend to mount weaker and shorter-lived responses to standard vaccines, leaving infants vulnerable during the months before they complete their vaccination series. TLR8 agonists are emerging as particularly effective adjuvants for overcoming this early-life hyporesponsiveness. Polymersomes loaded with a TLR8 agonist mimicked the immunomodulating effects of the live BCG vaccine and enhanced both innate and adaptive neonatal immune responses.²⁴

The most striking results come from a study in newborn rhesus macaques. When a TLR7/8 agonist called 3M-052 was mixed with the standard 13-valent pneumococcal conjugate vaccine and given as a single injection on the first day of life, the antibody response was roughly 10 to 100 times greater than a single birth dose of the vaccine alone. Antibody levels exceeded the threshold considered protective as early as 28 days of life.²⁵ Similar adjuvant formulations have also overcome neonatal hyporesponsiveness to acellular pertussis vaccination in mouse models, shifting the immune response toward a more protective profile.²⁶ These are still preclinical and early-stage results, but they point toward a future where a single dose at birth could provide protection that currently requires multiple boosters over months.

Designing TLR8 Inhibitors

On the other side of the coin, for diseases where TLR8 is driving harmful inflammation, researchers are developing selective inhibitors. The two-pocket binding architecture described earlier provides multiple targets for drug design. One approach targets the dimer interface where uridine binds, and structure-guided optimization has produced compounds with potency in the picomolar range that effectively shut down TLR8-mediated inflammation in human blood cells and in splenocytes from transgenic mice carrying the human receptor.²⁷

A second strategy targets the protein-protein interface needed for TLR8 dimerization. Triazole-based compounds designed to block this interaction suppress TLR8-driven inflammatory responses in both cell lines and primary immune cells from patients with rheumatoid arthritis.²⁸ A third, newer class uses an isoxazole scaffold identified through computational modeling. These compounds reduce MyD88 recruitment and suppress both NF-κB and IRF-dependent signaling downstream of TLR8.²⁹

None of these inhibitors have reached clinical trials yet, but the diversity of chemical scaffolds and mechanisms of action is encouraging. Because TLR8 shares structural similarity with TLR7, achieving selectivity between the two receptors is a persistent challenge in drug design. Small changes to agonist molecules can shift activity dramatically between TLR7 and TLR8.³⁰ The same principle works in reverse for antagonists: getting a compound that silences TLR8 without also disabling TLR7 requires precise structural tuning. Given TLR7’s distinct role in antiviral defense through plasmacytoid dendritic cells, accidentally blocking it while targeting TLR8 could leave patients more vulnerable to infections.